Anti-CD18 [H52]

Absolute Antibody

Anti-CD18 [H52]

7

This antibody binds disulfide-bonded loop (C386and C400) in the beta-2 integrin subunit. It is reported that the epitope of H52 is masked in the integrin Mac-1 and p150,95.

This antibody is successfully capable of inhibiting T cell, natural killer cells and complement receptor type 3 functions. Binding specificity of this antibody was confirmed with immunoprecipitation (PMID: 2580022). H52 mAb blocked 8E5-PHA-blast fusion in a dose-dependent manner with complete inhibition observed at concentrations above 3 microg/ml. Cell fusion (syncytium formation) is a major cytopathic effect of infection by human immunodeficiency virus (HIV). To determine the effect of the mAb on syncytium formation the LFA-1 expression of 8E5 cells and PHA-blasts was checked by flow cytometry. This mAb inhibited HIV-induced syncytium formation, however it did not block binding of gp120 to CD4 (PMID: 2543075). This mAb cross reacts with procine LFA-1 and profoundly inhibited mitogenic and allogenic stimulation of porcine T lymphocytes as well as cytotoxic T cell and natural killer (NK) cell function (PMID: 2481234). The expression of H52 epitope on beta-2 subunit isdependent on its interation with different alpha subunits of the leukocyte integrin LFA-1, Mac-1 and p150,95 and presence of calcium ions. The expression of the H52 epitope was examined by immunoprecipitation (PMID: 9808198).

Flow Cytometry, ImmunoPrecipitation, Neutralisation/Blocking

Block; Inhibit; FC; IP

Research Use Only

Monoclonal

H52

ITGB2

integrin subunit beta 2

CD18; cell surface adhesion glycoprotein (LFA-1/CR3/P150,959 beta subunit precursor); complement component 3 receptor 3 and 4 subunit; complement receptor C3 beta-subunit; integrin beta chain, beta 2; integrin beta-2; integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); LAD; LCAMB; leukocyte cell adhesion molecule CD18; leukocyte-associated antigens CD18/11A, CD18/11B, CD18/11C; LFA-1; MAC-1; MF17; MFI7; truncated integrin beta-2

Human

IgG1

Integrin beta-2

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.

Canine, Human, Porcine

Human, Pig, Dog

The original antibody was generated by immunizing BALB/c mice with human splenic adherent cells and later boosted with the same type of cells.

-20°C,2°C to 8°C

12352203